Raltegravir

FDA Drug Profile — Raltegravir

Raltegravir is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including Raltegravir. Available dosage forms: powder, tablet, film coated.

Drug details

Generic Name
Raltegravir
Brand Names
Raltegravir
Application Number
ANDA217990
Sponsor
Siegfried Evionnaz SA
NDC Codes
4
Dosage Forms
POWDER, TABLET, FILM COATED
Routes
ORAL
Active Ingredients
RALTEGRAVIR POTASSIUM

Indications and Usage

1 INDICATIONS AND USAGE ISENTRESS® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in patients 4 weeks of age and older. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response [see Clinical Studies (14) ] . ISENTRESS is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: In combination with other antiretroviral agents for the treatment of HIV-1 infection in patients 4 weeks of age and older ( 1 ). The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response ( 14 ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.